TRISCEND JAPAN Study

NCT ID: NCT05760989

Last Updated: 2024-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-06

Study Completion Date

2029-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, open, non-randomized, multicenter, clinical trial to evaluate the safety and effectiveness of the Edwards EWJ-202 transcatheter tricuspid valve replacement system in the treatment of patients with at least severe tricuspid regurgitation despite medical therapy. Subjects will be followed at discharge, 30 days, 6 months and annually through 5 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tricuspid Valve Regurgitation Heart Valve Diseases Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment with the Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System

Group Type EXPERIMENTAL

Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System

Intervention Type DEVICE

Replacement of the native tricuspid valve through a transcatheter approach

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System

Replacement of the native tricuspid valve through a transcatheter approach

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptomatic tricuspid regurgitation (TR) despite medical therapy
* TR graded as severe or greater
* Appropriate for transcatheter tricuspid valve replacement per the local heart team

Exclusion Criteria

* Tricuspid valve anatomic contraindications
* Need for emergent or urgent surgery or any planned cardiac surgery within the next 12 months
* Hemodynamic instability
* Refractory heart failure requiring advanced intervention
* Currently participating in another investigational study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yoshihiro Morino, MD

Role: STUDY_CHAIR

Iwate Medical University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kokura Memorial Hospital

Kitakyushu-shi, Fukuoka, Japan

Site Status

Tokai University Hospital

Isehara-shi, Kanagawa, Japan

Site Status

Sendai Kousei Hospital

Sendai, Miyagi, Japan

Site Status

Osaka Keisatsu Hospital

Osaka, Osaka, Japan

Site Status

Osaka University Hospital

Suita, Osaka, Japan

Site Status

National Cerebral and Cardiovascular Center

Suita-shi, Osaka, Japan

Site Status

Keio University Hospital

Shinjuku-Ku, Tokyo, Japan

Site Status

Tokyo Women's Medical University Hospital

Shinjuku-Ku, Tokyo, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.